Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 13/20 | 0.66 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.66 |
| ▸ | TGM2 | P21980 | 2/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.38 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.38 |
| ▸ | STK10 | O94804 | 3/20 | 0.37 |
| ▸ | SLK | Q9H2G2 | 3/20 | 0.37 |
| ▸ | PPOX | P50336 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4555257 | 0.81 | CES1 (0.57) | CES1DNMT1TGM2NSD2BCHE | |
| SCHEMBL29624609 | 0.80 | CES1 (1.00) | CES1DNMT1TGM2NSD2BCHE | |
| SCHEMBL136094 | 0.80 | CES1 (1.00) | CES1DNMT1TGM2NSD2BCHE | |
| SCHEMBL4554137 | 0.79 | ALDH1A1 (0.57) | CES1DNMT1TGM2NSD2BCHE | |
| SCHEMBL4555546 | 0.79 | CES1 (0.56) | CES1DNMT1TGM2NSD2BCHE | |
| SCHEMBL16832183 | 0.77 | CES1 (0.67) | CES1DNMT1TGM2NSD2BCHE | |
| SCHEMBL4555730 | 0.76 | CES1 (0.51) | CES1DNMT1TGM2NSD2BCHE | |
| SCHEMBL4555834 | 0.74 | CES1 (0.58) | CES1DNMT1TGM2NSD2BCHE | |
| SCHEMBL1274994 | 0.73 | CES1 (1.00) | CES1DNMT1TGM2NSD2BCHE | |
| SCHEMBL2372881 | 0.73 | CES1 (0.68) | CES1DNMT1TGM2NSD2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680607-A1 | BICYCLIC UREAS AS KINASE INHIBITORS | Incyte Corporation (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250304582-A1 | Bicyclic Ureas As Kinase Inhibitors | INCYTE CORPORATION | 2025-10-02 | — | — | US | disclosed |
| US-20240317744-A1 | Bicyclic Ureas As Kinase Inhibitors | INCYTE CORPORATION | 2024-09-26 | — | — | US | disclosed |
| WO-2024191996-A1 | BICYCLIC UREAS AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2024-09-19 | — | — | WO | disclosed |
| EP-2134692-A2 | QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION | Wyeth a Corporation of the State of Delaware (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20080255192-A1 | 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins | WYETH (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008121817-A2 | QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION | WYETH (US) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304582-A1 | Bicyclic Ureas As Kinase Inhibitors | JAK2, UCK2, ULK2 | CES1 3651/4885DNMT1 840/4885TGM2 906/4885 |
| US-20240317744-A1 | Bicyclic Ureas As Kinase Inhibitors | JAK2, UCK2, ULK2 | CES1 3651/4885DNMT1 840/4885TGM2 906/4885 |
| US-20080255192-A1 | 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins | VCAM1, ICAM1, SELE | CES1 1128/4885DNMT1 3114/4885TGM2 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.